TheEdgeResearch
Home / Stocks / KGET

CaliPharms, Inc. (KGET)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$474,349
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
5.30
52-Wk Range
0.000001-0.00004
CEO
Eric Watson
Country
US
Currency
USD

CaliPharms, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Temecula, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $474,349. On trailing twelve-month figures it carries a trailing P/E of -0.40, a net margin of -11861.4%. Its beta of 5.30 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.40
Price / Sales
39.53
Price / Book
-0.11
EV / EBITDA
-0.62
Gross margin
100.0%
Operating margin
-11222.7%
Net margin
-11861.4%
Return on equity
Debt / equity
-0.09
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
4
IPO date
2013-12-24
Headquarters
Temecula, CA, US
About CaliPharms, Inc.

CaliPharms, Inc. is an entity actively engaged in the medicinal cannabis industry across the United States. The company's primary focus lies within the THC and CBD-infused beverage sector. It rebranded to CaliPharms, Inc. in January 2017, having previously operated under the name Kleangas Energy Technologies, Inc. The corporate headquarters for CaliPharms, Inc. are located in Temecula, California.

Comparable companies

CaliPharms, Inc. is most often compared with the following Healthcare names:

CPYCFGTCPMTMWNSAUFPNLTRNWBSFRFFSPHUFTFZIWHTGF
More research on KGET
KGET technical analysis KGET TheEdge Score Compare against peers
Open full interactive analysis & DCF →